Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model
Michaela R. Reagan, Yuji Mishima, Siobhan Glavey, Yong Zhang, Salomon Manier, Zhi Ning Lu, Masoumeh Memarzadeh, Yu Zhang, Antonio Sacco, Yosra Aljawai, Jiantao Shi, Yu‐Tzu Tai, John E. Ready, David Kaplan, Aldo M. Roccaro, Irene M. Ghobrial (2014). Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. , 124(22), DOI: https://doi.org/10.1182/blood-2014-02-558007.
Article35 days agoIsatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Peter O’Gorman, Jacob P. Laubach, Ruth Clifford, Clifton C. Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Ølholm Vase, Keith W. Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emelia Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah J. Beaton, C. Prior, C. Piper, Bindu Krishnanivas, Emily J. Simpson, Ebrahim Karimi, Marissa Davis, Lourdes del Rosario McAlester, Amanda Allen, Paul Richardson (2025). Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-4030.
Article34 days agoIsatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Peter O’Gorman, Jacob P. Laubach, Ruth Clifford, Clifton C. Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Ølholm Vase, Keith W. Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emelia Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah J. Beaton, C. Prior, C. Piper, Bindu Krishnanivas, Emily J. Simpson, Ebrahim Karimi, Marissa Davis, Lourdes del Rosario McAlester, Amanda Allen, Paul Richardson (2025). Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-4030.
Article34 days ago